• Intuitive Q2 worldwide da Vinci procedures up 17% YoY
• 395 da Vinci systems placed in Q2, up from 341 in Q2 2024
• Da Vinci 5 systems reached 180 placements, up from 70 in Q2 2024
• Installed base increased 14% to 10,488 systems as of June 30, 2025
Intuitive Surgical (NASDAQ: ISRG) has reported robust financial results for the second quarter of 2025, with revenue surging 21% year-over-year to $2.44 billion. The company's worldwide da Vinci procedures grew by 17% during the period, with 395 new system placements, bringing the total installed base to 10,488 systems, a 14% increase from the previous year [1].
Key highlights of the quarter include GAAP net income of $658 million ($1.81 per diluted share) and non-GAAP net income of $798 million ($2.19 per diluted share). Intuitive secured important regulatory approvals, including European MDR certification and Japanese clearance for its da Vinci 5 surgical system. The company's full-year procedure growth guidance of 15.5-17% suggests management expects the strong momentum to continue, though potential margin pressure from tariffs is a concern [1].
The da Vinci 5 system, which was introduced in Q2 2024, demonstrated impressive market acceptance with 180 placements, more than doubling the 70 placements in the same period last year. The rapid adoption of the da Vinci 5 system indicates hospitals are seeing clear clinical and economic advantages, justifying the capital investment. The expanding installed base of 10,488 systems provides a solid foundation for future recurring revenue growth [1].
Intuitive's instruments and accessories revenue, which represents the company's most profitable recurring revenue stream, increased by 18% to $1.47 billion. The company ended the second quarter with $9.53 billion in cash, cash equivalents, and investments, an increase of $431 million during the quarter, primarily driven by cash generated from operations [1].
Intuitive's CEO, Dave Rosa, stated, "We’re pleased with our solid performance this quarter, highlighted by continued customer adoption of our newer and existing platforms, including da Vinci 5. We are committed to advancing care, and helping our customers provide better patient outcomes, better patient and care team experiences, broadening access to care and decreasing the total cost of care." [1]
The company's financial outlook for 2025 includes forward-looking, non-GAAP financial measures, which management uses in measuring performance. The outlook assumes the adverse impact from tariffs currently in effect and estimates the impact on the company's financial results [1].
References:
[1] https://www.stocktitan.net/news/ISRG/intuitive-announces-second-quarter-0ba2skdqykhk.html
Comments
No comments yet